KROS Q2 2021 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100,000

Gross Profit

-$10M-9883.0% margin

Operating Income

-$16M-15541.0% margin

Net Income

-$16M-15622.0% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$243M

Total Liabilities

$8M

Stockholders' Equity

$236M

Cash & Equivalents

$237M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100,000	$0	—
Gross Profit	-$10M	$0	—
Operating Income	-$16M	-$11M	-42.4%
Net Income	-$16M	-$11M	-45.2%